Patent application number | Description | Published |
20100094070 | ETHYLENE TRIMERIZATION USING A SUPPORTED CHROMIUM-TANTALUM CATALYST - Bimetallic, supported catalysts for production of 1-hexene from ethylene are manufactured by impregnating a porous, solid support material with at least one catalytic chromium compound and at least one catalytic tantalum compound. The bimetallic, supported catalysts have high catalytic turnover, high selectivity for 1-hexene production, a low tendency for metals to leach from the catalysts during manufacturing and use compared to catalysts manufactured using known techniques. Moreover, the catalysts can be reused in multiple synthesis runs. High turnover, high selectivity, and reusability improve yields and reduce the costs associated with producing 1-hexene from ethylene, while the absence of metal leaching reduces the potential environmental impacts of using toxic metal catalysts (e.g., chromium). | 04-15-2010 |
20100270239 | ZEOLITE MEMBRANE AND METHODS OF MAKING AND USING SAME FOR WATER DESALINATION - A novel zeolite membrane is manufactured using zeolite seeds that are deposited on a support material. The seeds are then further grown in a secondary growth step to form a membrane with inter-grown particles. The pore size of the zeolite membrane is in a range between 3 angstrom and 8 angstrom, which allows water to flow through the membrane at a relatively high flux rate while excluding dissolved ions. The novel zeolite membrane is surprisingly efficient for desalinating sea water using reverse osmosis. The zeolite membrane is capable of high rates of water flux rate and high percentage of ion rejection. | 10-28-2010 |
20120132591 | METHOD FOR DESALINATING WATER USING ZEOLITE MEMBRANE - A novel zeolite membrane is manufactured using zeolite seeds that are deposited on a support material. The seeds are then further grown in a secondary growth step to form a membrane with inter-grown particles. The pore size of the zeolite membrane is in a range between 3 angstrom and 8 angstrom, which allows water to flow through the membrane at a relatively high flux rate while excluding dissolved ions. The novel zeolite membrane is surprisingly efficient for desalinating sea water using reverse osmosis. The zeolite membrane is capable of high rates of water flux rate and high percentage of ion rejection. | 05-31-2012 |
20130248422 | HIGHLY STABLE HYDROCARBON-SOLUBLE MOLYBDENUM CATALYST PRECURSORS AND METHODS FOR MAKING SAME - Hydrocarbon-soluble molybdenum catalyst precursors include a plurality of molybdenum cations and a plurality of carboxylate anions having at least 8 carbon atoms. The carboxylate anions are alicyclic, aromatic, or branched, unsaturated and aliphatic, and can derived from carboxylic acids selected from 3-cyclopentylpropionic acid, cyclohexanebutyric acid, biphenyl-2-carboxylic acid, 4-heptylbenzoic acid, 5-phenylvaleric acid, geranic acid, 10-undecenoic acid, dodecanoic acid, and combinations thereof. The molybdenum salts have decomposition temperatures higher than 210° C. The catalyst precursors can form a hydroprocessing molybdenum sulfide catalyst in heavy oil feedstocks. Also disclosed are methods for making catalyst precursors and hydrocracking heavy oil using active catalysts. | 09-26-2013 |
Patent application number | Description | Published |
20100297080 | GENETIC MARKERS ASSOCIATED WITH INTERFERON-ALPHA RESPONSE - The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers arc useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients. | 11-25-2010 |
20120282224 | MARKERS ASSOCIATED WITH RIBAVIRIN-INDUCED ANEMIA - The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful, inter alia, to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with ribavirin, and in methods for selecting the most appropriate therapy for such patients. | 11-08-2012 |
20130251677 | GENETIC MARKERS ASSOCIATED WITH INTERFERON-ALPHA RESPONSE - The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients. | 09-26-2013 |
Patent application number | Description | Published |
20110117909 | METHOD AND SYSTEM FOR DYNAMICALLY SELECTING AND CONFIGURING VIRTUAL MODEMS (VMS) BASED ON PERFORMANCE METRICS IN A MULTI-SIM MULTI-STANDBY COMMUNICATION DEVICE - A multiple-subscriber identity module (multi-SIM) multi-standby communication device comprises a single radio resource unit shared by a plurality of virtual modems (VMs), each uniquely associated with a single one of a plurality of SIM cards. The access to radio resources in the single radio resource unit is controlled via a virtual modem controller (VMC). The VMC collects performance metrics such as requested service type and signal quality associated with each of the VMs. A VM is selected based on the collected performance metrics to perform a requested service. A serving VM is switched among the VMs based on the collected performance metrics. VM capabilities are dynamically configured based on the collected performance metrics. According to the collected performance metrics such as associated navigation information and requested service type, one or more VMs may be turned on or off, and certain VM capabilities may be enabled or disabled to save resources. | 05-19-2011 |
20110117944 | METHOD AND SYSTEM FOR TASK-LEVEL ACCESS ARBITRATION BETWEEN VIRTUAL MODEMS IN A MULTI-SIM MULTI-STANDBY COMMUNICATION DEVICE - A multiple-subscriber identity module (multi-SIM) multi-standby communication device comprises a single radio resource unit shared by a plurality of virtual modems (VMs), each uniquely associated with a single one of a plurality of SIM cards. The access to radio resources in the single radio resource unit is controlled for each VM task via a virtual modem controller (VMC). Upon receiving requests for tasks to access radio resources in the single radio resource unit, the VMC arbitrates the access based on task priority information, current activities associated with one or more of the plurality of VMs, and the radio resources available in the single radio resource unit. The access may be immediately accepted, accepted with a delay or rejected. With an immediate access, current activities may be suspended and then resumed once radio resources become available. With a delayed access, the VMC determines what time instants the access may be accepted. | 05-19-2011 |
20120015653 | METHOD AND SYSTEM FOR MITIGATION OF UNLISTED CELL IMPACTS IN IDLE MODE OF CELLULAR SYSTEMS - A UE, in an idle mode, receives pilot signals and synchronization signals from a serving cell and neighbor cells comprising neighbor cells listed and/or unlisted in a neighboring cell list. The UE validates each of the serving cell, the listed neighbor cells and the unlisted neighbor cells from the received signals. The UE performs cell measurement on the listed cells as well as the unlisted cells for multipath profiles and associated power levels. In instances where number of attempts of the cell measurements on the unlisted cells exceeds a threshold value, the UE may validate presence of the unlisted cells. The best available cell is selected from the listed cells and the unlisted for the UE to camp on. I/Q samples of the received signals are stored while measuring or monitoring the cells. The stored I/Q samples may be utilized to carry out baseband procedures through offline processing. | 01-19-2012 |
20130150014 | Background Paging Monitoring For Multiple SIM User Equipment - Systems and methods are presented to support operation of a multiple subscriber identity module (SIM) device. A first SIM may monitor paging indicators while a second SIM performs a data transfer or voice call. During the second SIM's data transfer or voice call, paging transition times are identified to transition communication resources to the first SIM for use in monitoring paging indicators. The transition time may be short so as to limit the impact on the second SIM's data transfer or voice call. When the first SIM receives a paging indicator indicating an incoming call, the device may retrieve caller identification information of the incoming call and automatically reject the incoming call. The communication resource may be returned to the second SIM to continue the data transfer or voice call. | 06-13-2013 |
20130150032 | Controlled Idle Mode Behavior in User Equipment Supporting Multiple Radio Access Techniques - User equipment includes techniques that may improve operation by selectively controlling access to particular radio access technologies (RATs) for the user equipment while it is operating in certain modes, such as idle mode. Once the user equipment is in a connected mode, and operating with significant uplink and\or downlink traffic activity, inter-RAT procedures can provide the benefits of access to multiple RATs. This technique is useful in many different environments, such as an environment that is predominantly 2G or 3G with 4G hot spot coverage. This technique may also be useful for providing enhanced operations in 2G/3G capable dual SIM user equipment running in a camped mode or other modes. The technique is not limited to 2G/3G/4G or any other particular standards, but may apply to any standards in a sequence of evolving or incrementally improving standards. | 06-13-2013 |
Patent application number | Description | Published |
20090187031 | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof - Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided. | 07-23-2009 |
20100068176 | HEPATITIS C VIRUS INHIBITORS - The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 03-18-2010 |
20100076191 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN - A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and processes for producing such novel forms are also provided. | 03-25-2010 |
20100080772 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 04-01-2010 |
20110294819 | Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein. | 12-01-2011 |
20130085147 | Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein. | 04-04-2013 |
20130224812 | Process for Resolving Cyclopropyl Diesters - The present disclosure provides a method for the stereospecific hydrolysis of racemic 1,1-dialkyloxycarbonylcyclopropanes. | 08-29-2013 |
Patent application number | Description | Published |
20080254128 | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound. | 10-16-2008 |
20100104637 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 04-29-2010 |
20100137348 | PHARMACEUTICAL FORMULATIONS: SALTS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 06-03-2010 |
20110092515 | MELT GRANULATION PROCESS - A process for preparing solid dosage forms that contain a quinoline compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate the quinoline compound with a granulation excipient. | 04-21-2011 |
20120015921 | PHARMACEUTICAL FORMULATIONS:SALTS OF 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-PHENYL-1,7-DIAZA-SP- IRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 01-19-2012 |
20120294935 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound. | 11-22-2012 |
20130122088 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 05-16-2013 |
20140088128 | PHARMACEUTICAL FORMULATIONS: SALTS OF 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-PHENYL-1,7-DIAZA-SP- IRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 03-27-2014 |
20150283121 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 10-08-2015 |